BCL2 and cervical cancer: Here we show that a previously non-cytotoxic concentration of cisplatin becomes toxic to cervical cancer cells and provides conceptual evidence to suggest that lower dosages of cisplatin may be a viable approach to treatment when combined with Bcl-2 silencing.